- Home
- PFL vs EBS Comparison
PFL vs EBS Comparison
Compare PFL & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFL
- EBS
- Stock Information
- Founded
- PFL 2003
- EBS 1998
- Country
- PFL United States
- EBS United States
- Employees
- PFL N/A
- EBS N/A
- Industry
- PFL Finance Companies
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- PFL Finance
- EBS Health Care
- Exchange
- PFL Nasdaq
- EBS Nasdaq
- Market Cap
- PFL 374.5M
- EBS 359.3M
- IPO Year
- PFL N/A
- EBS 2006
- Fundamental
- Price
- PFL $8.55
- EBS $7.59
- Analyst Decision
- PFL
- EBS Strong Buy
- Analyst Count
- PFL 0
- EBS 3
- Target Price
- PFL N/A
- EBS $14.33
- AVG Volume (30 Days)
- PFL 113.7K
- EBS 1.2M
- Earning Date
- PFL 01-01-0001
- EBS 11-05-2025
- Dividend Yield
- PFL 11.53%
- EBS N/A
- EPS Growth
- PFL N/A
- EBS N/A
- EPS
- PFL N/A
- EBS 2.53
- Revenue
- PFL N/A
- EBS $851,600,000.00
- Revenue This Year
- PFL N/A
- EBS N/A
- Revenue Next Year
- PFL N/A
- EBS $19.24
- P/E Ratio
- PFL N/A
- EBS $3.00
- Revenue Growth
- PFL N/A
- EBS N/A
- 52 Week Low
- PFL $6.98
- EBS $4.02
- 52 Week High
- PFL $8.62
- EBS $12.73
- Technical
- Relative Strength Index (RSI)
- PFL 69.06
- EBS 41.67
- Support Level
- PFL $8.42
- EBS $8.16
- Resistance Level
- PFL $8.49
- EBS $8.62
- Average True Range (ATR)
- PFL 0.05
- EBS 0.39
- MACD
- PFL 0.00
- EBS -0.22
- Stochastic Oscillator
- PFL 86.67
- EBS 3.72
About PFL PIMCO Income Strategy Fund Shares of Beneficial Interest
PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. It seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.